Clinical review 166: Growth hormone receptor antagonists.

J Clin Endocrinol Metab

Department of Internal Medicine, Diakonessenhuis Utrecht, 3582 KE Utrecht, The Netherlands.

Published: April 2004

Download full-text PDF

Source
http://dx.doi.org/10.1210/jc.2002-022049DOI Listing

Publication Analysis

Top Keywords

clinical review
4
review 166
4
166 growth
4
growth hormone
4
hormone receptor
4
receptor antagonists
4
clinical
1
0
1
growth
1
hormone
1

Similar Publications

Introduction: Guided surgery for immediate anterior implants aims to reduce the time required for aesthetic and functional immediate loading. However, the limited surface area of anterior teeth for guide stabilization may affect the accuracy of implant positioning. This in vitro study evaluated the effect of the number of supporting teeth on the accuracy of immediate implants in the maxillary central incisor region.

View Article and Find Full Text PDF

Background: Cutaneous melanoma is one of the most invasive and lethal skin malignant tumors. Compared to primary melanoma, metastatic melanoma (MM) presents poorer treatment outcomes and a higher mortality rate. The tumor microenvironment (TME) plays a critical role in MM progression and immunotherapy resistance.

View Article and Find Full Text PDF

No cost-effectiveness information of preventive strategies for mother-to-child transmission (MTCT) of hepatitis B virus (HBV) has existed for policy decision making. This study aimed to compare the cost-effectiveness of alternative strategies to prevent MTCT of HBV in Vietnam. Cost-utility analysis using a hybrid decision-tree and Markov model were performed from healthcare system and societal perspectives.

View Article and Find Full Text PDF

Background: Gastrointestinal subepithelial lesions (SELs) range from benign to malignant. Endoscopic ultrasound (EUS)-guided fine-needle biopsy (EUS-FNB) is used widely for pathological diagnosis of SELs. Early diagnosis and treatment are important because all Gastrointestinal stromal tumors (GISTs) have some degree of malignant potential.

View Article and Find Full Text PDF

Background: Excessive submental fat under the chin is a known aesthetic concern because of its negative impact on facial appearance and psychological well-being. AYP-101 is a newly developed injectable agent containing 93% soybean phosphatidylcholine (SPC) designed to reduce submental fat. We conducted a phase 1 study to evaluate the safety, pharmacokinetic (PK), and lipid profile effects of AYP-101.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!